Cannabinoids and IBS: What Does the Research Actually Say?
Cannabinoids have become an increasingly common topic in conversations surrounding chronic pain, anxiety, sleep, and digestive health. But can cannabinoids actually help irritable bowel syndrome (IBS) symptoms?
Before discussing the research surrounding cannabinoids and IBS, it is important to first understand what cannabinoids are and why the legal landscape surrounding their use remains complicated.
What Are Cannabinoids?
Cannabinoids are naturally occurring compounds found in cannabis and hemp plants, including Cannabis sativa, Cannabis indica, Cannabis ruderalis, and hemp (Cannabis sativa L). Researchers have identified hundreds of phytochemicals within these plants, with cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) being the most widely recognized.
THC is the compound primarily responsible for the psychoactive “high” associated with cannabis use, while CBD is generally considered non-intoxicating.
The Legal Status of CBD and THC
In both the United States and internationally, cannabinoid laws remain complex and continue evolving.
Some U.S. states have legalized medicinal cannabis use, others allow recreational use, and some permit only CBD-containing products. Even products marketed as “CBD” may legally contain small amounts of THC—typically up to 0.3% depending on state and federal regulations.
Because of this, individuals using CBD products may still test positive for THC on drug screenings.
It is also important to understand that most over-the-counter cannabinoid products are not FDA-regulated in the same way as prescription medications are.
Currently, the FDA has approved:
- One cannabis-derived medication: Epidiolex (cannabidiol)
- Three synthetic cannabinoid-related medications: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone)
These medications are available only by prescription for specific medical indications.
Outside of these prescription products, studies have shown that some commercially available CBD and THC products may contain inaccurate labeling regarding cannabinoid content and potency.
The Endocannabinoid System and Gut Health
Humans naturally possess an endocannabinoid system (ECS), which contains cannabinoid receptors distributed throughout the body, including the gastrointestinal tract.
The ECS plays a role in regulating several physiological processes, including:
- Pain perception
- Appetite
- Mood
- Inflammation
- Gastrointestinal function
Because IBS involves altered gut motility, abdominal pain, and gut-brain interactions, researchers have become increasingly interested in whether cannabinoids may influence IBS symptoms.
The Theory of Clinical Endocannabinoid Deficiency
One proposed explanation for why cannabinoids might influence IBS symptoms is known as the theory of clinical endocannabinoid deficiency (CED).
This theory suggests that some chronic conditions may involve deficiencies in endocannabinoid signaling, similar to how other medical disorders may involve neurotransmitter deficiencies. According to this hypothesis, low endocannabinoid activity could potentially contribute to symptoms seen in disorders such as IBS, migraines, and fibromyalgia.
What Does the Research on Cannabinoids and IBS Show?
Research surrounding cannabinoids and IBS remains extremely limited, particularly within the United States, where cannabis remains federally illegal.
As a result, there are currently no large-scale randomized controlled trials evaluating cannabinoids specifically as a standardized treatment for IBS.
Many available studies instead examine associations between Cannabis Use Disorder (CUD) and IBS symptoms or hospitalization rates. Interestingly, findings have been mixed. Some studies report correlations between cannabis use and increased IBS-related symptoms or hospitalizations, while others suggest improvements in symptoms and reduced hospitalizations.
One reason these findings appear contradictory is that many of the studies are retrospective observational studies rather than controlled clinical trials. These studies often rely on hospitalization records and collected patient data rather than standardized cannabinoid dosing and symptom monitoring.
Even studies suggesting potential benefits consistently note that more rigorous research is needed before cannabinoids can be recommended as a standard IBS treatment. Researchers still need clearer data regarding:
- Long-term safety
- Effectiveness
- Appropriate dosing
- Delivery methods
- Side effects
- Therapeutic windows
- Toxicity thresholds
What Does This Mean for People with IBS?
Right now, there simply is not enough high-quality evidence to definitively say cannabinoids can reliably treat IBS symptoms.
That does not necessarily mean cannabinoids are ineffective for every individual. Many people report anecdotal improvement in symptoms such as abdominal pain, nausea, appetite changes, or stress-related symptom flares. However, responses appear highly individualized, and research has not yet established consistent recommendations.
If individuals choose to explore cannabinoid products where legally permitted, it may be helpful to:
- Review state and local laws
- Request third-party quality testing information
- Verify CBD and THC concentrations
- Understand carrier ingredients in oils or edibles
- Monitor symptoms carefully with a journal or log
It is also important to recognize that topical cannabinoid products are unlikely to directly affect IBS symptoms, since they generally do not penetrate deeply enough to influence gastrointestinal receptors.
The Importance of Talking With Your Healthcare Team
As with any complementary therapy, individuals considering cannabinoid use should discuss it with their healthcare providers—especially if they take prescription medications or have underlying medical conditions.
Because cannabinoids may interact with medications, affect mental health, or produce side effects, individualized guidance is important.
The Bottom Line
Interest in cannabinoids and gut health continues to grow as researchers learn more about the endocannabinoid system and its relationship to gastrointestinal function.
While some preliminary findings and anecdotal reports suggest cannabinoids may influence IBS symptoms in certain individuals, current evidence remains limited and inconsistent. Larger, controlled clinical trials are still needed before cannabinoids can be recommended as a standardized IBS treatment.
For now, the safest approach is informed decision-making, careful symptom monitoring, and open communication with qualified healthcare professionals.
- Black, C. J., Joseph, N., & Ford, A. C. (2020). Efficacy of cannabis and cannabinoids in irritable bowel syndrome: A systematic review and meta-analysis. Complementary Therapies in Medicine, 51, 102495. https://doi.org/10.1016/j.ctim.2020.102495
- Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709. https://doi.org/10.1001/jama.2017.11909
- Desai, P., Mbachi, C., Vohra, I., Salazar, M., Mathew, M., Randhawa, T., Haque, Z., Wang, Y., Attar, B., & Paintsil, I. (2020). Association Between Cannabis Use and Healthcare Utilization in Patients With Irritable Bowel Syndrome: A Retrospective Cohort Study. Cureus, 12(5), e8008. https://doi.org/10.7759/cureus.8008
- Patel, R. S., Goyal, H., Satodiya, R., & Tankersley, W. E. (2020). Relationship of Cannabis Use Disorder and Irritable Bowel Syndrome (IBS): An Analysis of 6.8 Million Hospitalizations in the United States. Substance use & misuse, 55(2), 281–290. https://doi.org/10.1080/10826084.2019.1664591
- Pertwee, R. G. (2016). The pharmacology of cannabinoid receptors and their ligands: An overview. Cannabis and Cannabinoid Research, 1(1), 70–84. https://doi.org/10.1089/can.2015.0012
- Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165. https://doi.org/10.1089/can.2016.0009
Recipes
Products
Comments
Join The Conversation...